Expressiveness of global coagulation parameters in dilutional coagulopathy.
BACKGROUND
Plasma-free volume replacement in haemorrhage often results in dilutional coagulopathy. Prothrombin time index (PTI) and activated partial thromboplastin time (aPTT) are used for monitoring haemostasis but have not yet been clinically evaluated. Our aim was to investigate the effects of haemodilution on the course of global coagulation tests and clotting factors (CFs).


METHODS
Blood samples from each of 10 volunteers were diluted with sodium chloride 0.9% (saline) or 6% hydroxyethyl starch 130/0.4 (HAES) by 30-80%. PTI, aPTT, CF, and the thrombelastometric parameters (ROTEM(®)) coagulation time (CT) and maximum clot firmness (MCF) were determined.


RESULTS
Dilution-dependent CF decreased in an almost linear manner and was not influenced by the diluent. Critically low activities for CF of ∼30% and a fibrinogen concentration <100 mg dl(-1) were measured at dilutions of between 60% and 75%. Critically low CF activities of about 30% were indicated by a PTI of 35-40%. PTI and MCF decreased continuously, demonstrating a good correlation with CF activities and fibrinogen. aPTT and CT showed a linear course up to a dilution of 65-75% corresponding to CF activities of 30-40%. Thereafter, values became pathological. PTI and aPTT were not influenced by the type of diluent, whereas the diluents had profound differences on results of thromboelastometry.


CONCLUSIONS
PTI and MCF are useful for monitoring dilution and intervention points. aPTT and CT reflect intervention points when showing pathological values. The type of diluents does not seem to interfere with PTI and aPTT, but HAES impairs haemostasis in ROTEM(®) more profoundly than saline.
Weiss
G
G
Department of Anaesthesiology, Munich University Hospital, Ludwig-Maximilians-University Munich, Nussbaumstrasse 20, 80336 Munich, Germany.
Lison
S
S
Spannagl
M
M
Heindl
B
B
D000328:Adult; D001778:Blood Coagulation Disorders / Q000175:diagnosis* / Q000209:etiology*; D005260:Female; D006438:Hemodilution / Q000009:adverse effects*; D006487:Hemostasis; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D011517:Prothrombin Time; D012965:Sodium Chloride / Q000009:adverse effects; D013916:Thrombelastography
D006895:Hydroxyethyl Starch Derivatives; D012965:Sodium Chloride